Loading...
1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
Paz-Ares, L Socinski, M Shahidi, J Hozak, R Soldatenkova, V Thatcher, Nick Hirsch, F
Paz-Ares, L
Socinski, M
Shahidi, J
Hozak, R
Soldatenkova, V
Thatcher, Nick
Hirsch, F
Citations
Altmetric:
Abstract
Description
Date
2016-04
Publisher
Collections
Keywords
Type
Article
Citation
1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). 2016, 11 (4 Suppl):S153 J Thorac Oncol